Achillion Announces Janssen Initiated Phase 2a Study to Evaluate Combination of AL-335, ACH-3102, and Simeprevir for Treatment of Genotype 1 Chronic HCV
October 16, 2015 at 06:07 AM EDT
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies ...
